The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

OpenAI reveals a sleek rebrand featuring a refined logo, custom typeface, and cohesive design, blending human creativity with ...

Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to ...

Sisters Network® Inc. (SNI), the only national African American breast cancer survivorship organization with 25+ survivor run ...

The Alzheimer’s Association advised against diagnosing the disease on biomarkers alone, but other experts said the genie ...

Eisai (ESAIY) and Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has approved the Supplemental Biologics License ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...